Academic Journal
Q1Clinical and Molecular Hepatology
About Clinical and Molecular Hepatology
Clinical and Molecular Hepatology is a scholarly journal published by Korean Association for the Study of the Liver. SCImago 2025 lists it in Q1, with an SJR of 4.937 and H-index of 74.
Coverage: 2012-2026. Research categories: Hepatology (Q1); Medicine (miscellaneous) (Q1); Molecular Biology (Q1).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
Toward AI Virtual Cells for Hepatology: Representation, Generation, Dynamics, and Intervention in Single-Cell Models
Youngseok Choi, In Gyeong Koh, Murim Choi, Joon-Yong An et al.
2026-09-17 · DOI: 10.3350/cmh.2026.0820Hepatocyte Plasticity in Liver Health and Disease: Zonation, Regeneration, Lineage Conversion, and Hepatic Malignancy
Xuan Wang, Yunfang Wang, Shuyong Wang
2026-09-11 · DOI: 10.3350/cmh.2026.0630RNAi-mediated HBV antigen shutdown enhances the antiviral immune effects of PEGIFNα via T and B cell crosstalk remodeling
Wenjing Zai, Kongying Hu, Mengying He, Ziyang Song et al.
2026-09-11 · DOI: 10.3350/cmh.2026.0385Risk Assessment in MASLD and MetALD: Current Approaches and Future Directions
Huapeng Lin, Haixia Wang, Kangsen Yang, Min Li et al.
2026-08-28 · DOI: 10.3350/cmh.2026.0398Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Seonjeong Woo, Donghyeon Kim, Chansik An, Sanghoon Jung et al.
2026-08-21 · DOI: 10.3350/cmh.2026.0866Letter regarding “Lack of Association Between Rifaximin and Drug-resistant Infections: A global multicenter inpatient cirrhosis cohort”
Lijun Ge, Yu Xu, Jinfang Yan
2026-08-20 · DOI: 10.3350/cmh.2026.07612026 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
2026-08-19 · DOI: 10.3350/cmh.2026.0943Alcohol-Aware Risk Stratification and Subtype-Specific Care Pathways Across MASLD, MetALD, and ALD
Hyo Young Lee, Eileen Laurel Yoon, Dae Won Jun
2026-08-14 · DOI: 10.3350/cmh.2026.0659Comprehensive Radiopathological and Molecular Review of HCC: Expanding on the WHO, 6th Edition
Hyungjin Rhee, Young Nyun Park
2026-08-11 · DOI: 10.3350/cmh.2026.0431Long-Term Liver Outcomes in Wilson’s Disease: Predictors of Survival and Hepatocellular Carcinoma
Chien-Ting Hsu, Sung-Pin Fan, Jia-Feng Wu, Chin-Chang Huang et al.
2026-08-11 · DOI: 10.3350/cmh.2026.0402Viral load rather than transaminase: an international perspective on the KASL–EALA 2026 guideline for chronic hepatitis B
Tatsuya Kanto, Fabien Zoulim, Ming-Lung Yu
2026-08-05 · DOI: 10.3350/cmh.2026.0908Dynamic Transitions in Steatotic Liver Disease Subtypes and Risk of Liver-Related Events: A Nationwide Cohort Study
Yewan Park, Jooyi Jung, Seungbong Han, Hyeyeon Hong et al.
2026-07-30 · DOI: 10.3350/cmh.2026.0408External beam radiotherapy versus local ablation therapy for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis
Sun Hyun Bae, Seo Hee Choi, Sang Min Yoon, Jeong Il Yu et al.
2026-07-30 · DOI: 10.3350/cmh.2026.0535Artificial Intelligence and Generative Models in Hepatology: From Large Language Models to Digital Pathology in Liver Disease Diagnosis and Treatment
Nana Peng, Mary Yue Wang, Sherlot Juan Song, Jimmy Che-To Lai et al.
2026-07-23 · DOI: 10.3350/cmh.2026.0258Current Burden of Hepatitis B Virus Infection in the United States, 2017–2023
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed et al.
2026-07-23 · DOI: 10.3350/cmh.2026.0817Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study
Axel Wester, Emilie Toresson Grip, Rupesh Rajani, Anthony A. Matthews et al.
2026-07-15 · DOI: 10.3350/cmh.2026.0286Global Epidemiological Patterns and Disease Burden of MASLD, MetALD, and ALD
Pojsakorn Danpanichkul, Matheus Souza, Primrose Tothanarungroj, Aijaz Ahmed et al.
2026-07-15 · DOI: 10.3350/cmh.2026.0444Steatotic Liver Disease: Non-Invasive Assessment and Biomarkers Across MASLD, MetALD and ALD
Monica Tincopa, Rohit Loomba
2026-07-15 · DOI: 10.3350/cmh.2026.0415Beyond the single model: Critical considerations for translating HCC triplet immunotherapy from bench to bedside: Letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma”
Han Zhuo, Yue Teng, Zhongming Tan
2026-07-01 · DOI: 10.3350/cmh.2025.1398Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”
Teng-Yu Lee, Chun-Ying Wu
2026-07-01 · DOI: 10.3350/cmh.2026.0007Reviews
Community Reviews
Version History
September 10, 2026 at 10:08 am
September 10, 2026